Correction to: Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer

Fernanda Bueno¹ · María Gabriela García Falcone¹ · Mirna Angela Peñaloza¹ · Erika Abelleira¹ · Fabián Pitoia¹

Published online: 14 September 2020

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Endocrine

<https://doi.org/10.1007/s12020-019-02112-7>

The original version of this article unfortunately contained a mistake in Table 3. The initial levels of Tg Ab was incorrectly transcribed. The corrected Table 3 is given below.

The original article can be found online at <https://doi.org/10.1007/s12020-019-02112-7>.

✉ Fabián Pitoia
fpitoia@intramed.net

¹ Division of Endocrinology, Hospital de Clínicas-University of Buenos Aires, Buenos Aires, Argentina

Table 3 Baseline characteristics and comparison of the responses to therapy in patients with detectable TgAb with and without radioiodine remnant ablation

	Radioiodine remnant ablation (RA)		<i>p</i>
	Without RA (<i>n</i> = 23)	With RA (<i>n</i> = 30)	
Sex (<i>n</i> , %)			
Female	18 (78.3)	27 (90)	0.237 ^a
Male	5 (21.7)	3 (10)	
Age (years)			
Median (range)	42 (27–69)	44 (29–76)	0.2697 ^b
Histology (<i>n</i> , %)			
Papillary	22 (95.7)	30 (100)	0.249 ^a
Follicular	1 (4.3)	0	
Lymphocytic thyroiditis (<i>n</i> , %)	17 (73.9)	14 (46.7)	0.741 ^a
Initial TgAb median IU/ml (range)	194 (0–2000)	98 (0–1180)	0.1435 ^b
TgAb trend at 12 months (<i>n</i> , %)			
Undetectable	5 (21.7)	1 (3.3)	0.006 ^a
Decreased	14 (60.9)	15 (50)	
Stable	1 (4.3)	6 (20)	
Increased	3 (13)	2 (6.7)	
Unknown	0	6 (20)	
Initial response to treatment (<i>n</i> , %)			
Excellent response	8 (34.8)	7 (23.4)	0.610 ^a
Indeterminate response	15 (65.2)	21 (70)	
Biochemical incomplete	0	1 (3.3)	
Structural incomplete	0	1 (3.3)	
Clinical status at 36 months of follow up			
NED (<i>n</i> , %)	8 (34.8)	9 (30)	0.442 ^a
Indeterminate (<i>n</i> , %)	15 (65.2)	19 (63.3)	
Biochemical incomplete (<i>n</i> , %)	0	0	
Structural incomplete (<i>n</i> , %)	0	2 (6.7)	
Time to undetectable TgAb (months)			
Median (range)	11.25 (6–21)	16 (11–36)	0.0232 ^b
Time of follow-up (months)			
Median (range)	27 (16–42)	82 (27–210)	

RA radioiodine remnant ablation, TgAb anti-thyroglobulin antibodies, NED no evidence of disease

^a*p* values were determined by the χ^2 test

^b*p* values were determined by the Mann–Whitney *U* test